Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
05/2003
05/22/2003US20030096776 Inhibiting the division of a malignant mammalian cell and for modulating the effects of cellular aging
05/22/2003US20030096775 Treating multiple sclerosis, infection, or atherosclerosis
05/22/2003US20030096773 Antisense modulation of acyl coenzyme a cholesterol acyltransferase-1 expression
05/22/2003US20030096772 Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
05/22/2003US20030096771 8-50 nucleobases targeted to a nucleic acid molecule encoding hormone-sensitive lipase to hybridize with and inhibit expression
05/22/2003US20030096769 Genetic molecules capable of modulating growth factor interaction with its receptor on epidermal keratinocytes
05/22/2003US20030096767 Strategy for suppressing the expression of an endogeneous gene by using compounds that are able to bind to the non-coding regions of the gene to be suppressed
05/22/2003US20030096761 Angiotensin converting enzyme (ACE) and/or neutral endopeptidase (NEP); organic acids and salts thereof, sodium lauryl sulfate and palmitoyl carnitine enhancers used in treating cardiovascular disorders
05/22/2003US20030096760 Treating a bone resorption disease by administering a compound which forms a covalent bond or link to cys185 of the src SH2 domain
05/22/2003US20030096759 Novel elastase inhibitors
05/22/2003US20030096758 Anticarcinogenic agents
05/22/2003US20030096757 Matrix metalloproteinases inhibitor peptides having sequences related to cleavage regions of the proenzyme forms of matrix
05/22/2003US20030096756 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
05/22/2003US20030096755 Suppression of inhibitors
05/22/2003US20030096754 Vascular endothelial growth factor variants
05/22/2003US20030096753 Therapeutic agent
05/22/2003US20030096752 Net charge of -3-3 at pH 7 and with the amino acids arginine15 or arginine15-alanine17 in the binding region; serine protease inhibitors
05/22/2003US20030096751 G-protein coupled receptor polynucleotides and methods of use thereof
05/22/2003US20030096750 Recombinant DNA of a gene having a DNA sequence or amino acid sequence; antitumor agents
05/22/2003US20030096749 Human cytokine receptor
05/22/2003US20030096748 Methods and compositions for the treatment of diseases associated with signal transduction aberrations
05/22/2003US20030096747 Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
05/22/2003US20030096746 Compounds and methods for inhibiting cancer metastasis
05/22/2003US20030096745 A conjugated cecropins and magainins with one or more replaced peptides; bactericides, fungicides and anticarcinogenic agent; nontoxic
05/22/2003US20030096744 Secreted and transmembrane polypeptides and nucleic acids encoding the same
05/22/2003US20030096742 Secreted and transmembrane polypeptides and nucleic acids encoding the same
05/22/2003US20030096741 Enhanced mineral delivery
05/22/2003US20030096740 A dental enamel proteins used as therapeutic or prophylactic agents for the treatment or prevention of cancer or tumor
05/22/2003US20030096739 Nuclear receptor-mediated introduction of a PNA into cell nuclei
05/22/2003US20030096736 Lactoferrin for age related disorders in humans
05/22/2003US20030096733 Novel drug targets for arthritis
05/22/2003US20030096732 Regulating gene expression of telomerase reverse transcriptase (TERT); therapeutic agent screening applications
05/22/2003US20030096413 Storage of corneas in culture; obtain nutrient broth containing nerve growth factor, deposit corneas in broth, store tissue
05/22/2003US20030096400 N-terminally chemically modified protein compositions and methods
05/22/2003US20030096390 Novel lipase genes
05/22/2003US20030096387 Contacting the isomerase with a compound having the structure: A-X-A, where A is radical which mimics the steric and electronic properties of phosphoserin and/or phosphothreonine residue, X= spacer, R is cyclic, heterocylic or aryl ring
05/22/2003US20030096386 Nuclelotide sequences coding polypeptide for use in the treatment, diagnosis and prevention of tumors and cell proliferative disorder
05/22/2003US20030096376 Generation of autoinducer-2; obtain S-adenosylhomocysteine, incubate with preferential protein, allow conversion of s-adenosylhomocysteine to autoinducer-2
05/22/2003US20030096368 Nucleotide sequences coding bactericide for use in the treatment and prevention of neisseria infections
05/22/2003US20030096365 Biochemical and genetic characterization of propionicin T1
05/22/2003US20030096355 Nuclleotide sequences coding polypeptide for use in the treatment of cachexia, toxic shock syndrome, inflammation, rheumatoid and osteoarthritis
05/22/2003US20030096354 Synthetic polypeptide ligand for use in the treatment of cardiovascular, tumor, viral and hypertensive disorders
05/22/2003US20030096352 Nucleotide sequences coding polypeptides for use in the treatment and prevention of viral and bacterial disease
05/22/2003US20030096350 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
05/22/2003US20030096348 DNA molecules encoding mammalian nuclear receptor protein, nNR5
05/22/2003US20030096347 Polynucleotides encoding two novel human G-protein coupled receptors, HGPRBMY28 and HGPRBMY29, and splice variants thereof
05/22/2003US20030096346 Nucleic acids, proteins, and antibodies
05/22/2003US20030096344 Therapeutic agent for use in the diagnosis and treatment of cancer and cell proliferative disorders
05/22/2003US20030096343 Modular assembly of antibody genes, antibodies prepared thereby and use
05/22/2003US20030096340 Nucleotide sequences coding polypeptide for use in the treatment, diagnosi and prevention of skin, kidney and cell proliferative disorders
05/22/2003US20030096338 Protein conjugate for use in the treatment of blood disorder
05/22/2003US20030096337 Polynucleotides encoding a human S100 protein
05/22/2003US20030096330 Genetically engineered cell for use as tool in controlling bacterial propagation and infection
05/22/2003US20030096326 Gene product over expressed in cancer cells
05/22/2003US20030096314 Propagation of dendritic cells in culture; obtain pluripotent cells, inoculate nutrient broth, propagate and recover mature dendritic cells
05/22/2003US20030096305 Nucleotide sequences coding polypeptide for use in the treatment and diagnosis of brain, viral and respiratory disorders
05/22/2003US20030096299 Natural ligand of G protein coupled receptor ChemR23 and uses thereof
05/22/2003US20030096297 Method for identifying inhibitors of G protein coupled receptor signaling
05/22/2003US20030096288 Nucleotide sequences coding polypeptide for use in the treatment of cancer and nervous system disorders
05/22/2003US20030096287 Oligonucleotide for use as diagnostic tool in genetic engineering
05/22/2003US20030096286 Oligoribonucleotides and ribonucleases for cleaving RNA
05/22/2003US20030096279 Nuccleotide sequences coding polypeptide for use in the treatment of nervous system disorders
05/22/2003US20030096272 Genes regulated by peroxisome proliferator-activated receptor gamma agonist
05/22/2003US20030096270 Diagnosing respiratory disorder; obtain cells, monitor expression of marker gene, determine sequence, compare to control, detect polymorphism in polypeptide or nucleotide, presence of polymorphism indicates respiratory disorders
05/22/2003US20030096266 Hydrophobic biopolymer for use in the treatment of infections, blood, inflammatory and muscular disorders
05/22/2003US20030096250 Nucleotide sequences coding polypeptide for use in the prevention of bacterial infection of mammals
05/22/2003US20030096247 Human cDNAs and proteins and uses thereof
05/22/2003US20030096238 Compositions and methods relating to gynecologic cancer specific genes
05/22/2003US20030096236 Determining common functional alleles in a population and uses therefore
05/22/2003US20030096233 Secreted and transmembrane polypeptides and nucleic acids encoding the same
05/22/2003US20030096226 Use of a native epitope for selecting evolved binding members from a library of mutants of a protein capable of binding to said epitope
05/22/2003US20030096225 Recovering preferential protein from library; obtain cell, transform with vector, express vector, isolate preferential protein
05/22/2003US20030096030 Extracting materials from the shell of Xanthoceras sorbifolia Bunge and applying the extracted materials to making drugs and functional foods
05/22/2003US20030096022 Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor
05/22/2003US20030096011 Wet milling suspension of labile agent dispersed in biocompatible polymer and solvent; drying to form solid polymer/labile agent matrix
05/22/2003US20030096002 Delivery system for biological component
05/22/2003US20030095994 Resorbable extracellular matrix containing collagen I and collagen II for reconstruction of cartilage
05/22/2003US20030095989 Chimeric cytolytic viruses for cancer treatment
05/22/2003US20030095983 Treating obesity, insulin resistance, and type II diabetes
05/22/2003US20030095979 Xn-PeptideL-Xm, where X is Gly, Ala, Val, Leu, Ile, Pro, Phe, Tyr, Trp, Cys, Met, Glu or Asp; and PeptideL is a potentially immunogenic fragment; and a polycationic material; vaccines
05/22/2003US20030095978 Novel adherence factors of non pathogenic microorganisms and applications thereof for screening microorganisms for specific probiotic properties; novel pharmaceutical compositions and food additives comprising such microorganisms and adherence factors
05/22/2003US20030095972 Administration of phosphorylated Mammastatin having a molecular weight of 53 kDa or 49 kDa; the polypeptide is specifically reactive with monoclonal antibody 7G6 that is produced from hybridoma ATCC No. HB10152
05/22/2003US20030095971 Compositions and methods for WT1 specific immunotherapy
05/22/2003US20030095969 Administering an anti-VLA-4 antibody, a monoclonal antibody recognizing VLA-4, or a soluble VCAM-1 polypeptide.
05/22/2003US20030095968 Viral encoded semaphorin protein receptor DNA and polypeptides
05/22/2003US20030095967 BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
05/22/2003US20030095966 Method of blocking tissue destruction by autoreactive T cells
05/22/2003US20030095964 Process for producing humanized chimera antibody
05/22/2003US20030095963 Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restriced differentiation antigen for treatment of B cell lymphoma
05/22/2003US20030095962 Chimeric cell-surface receptors that undergo antigen-induced association
05/22/2003US20030095961 Composition and method for treating disease by increasing activated alpha2 macroglobulin in the blood and extravascular tissue
05/22/2003US20030095960 Three human transferases, polynucleotides that identify and encode them, expression vectors, host cells, antibodies, agonists, and antagonists.
05/22/2003US20030095959 Topical skin composition
05/22/2003US20030095956 Methods of proliferating undifferentiated neural cells
05/22/2003US20030095954 Growth factor gene fused with secretory signal sequence is introduced into fibroblasts ex-vivo using adenovirus vector; infecting cultured non-hematocytes with the vector; administering the cells
05/22/2003US20030095953 Methods of reversing drug resistance in cancer cells
05/22/2003US20030095949 Introducing into cells viral particles or vector that comprise a polynucleotide encoding a serum protein.
05/22/2003US20030095947 Compositions and methods for elimination of unwanted cells
05/22/2003US20030095946 Il-18 as an osteoclastgenic inhibitor
05/22/2003US20030095928 Nanoparticulate insulin
1 ... 1841 1842 1843 1844 1845 1846 1847 1848 1849 1850 1851 1852 1853 1854 1855 1856 1857 1858 1859 1860 1861 ... 3163